Lipocine Inc (LPCN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.45+1.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LPCN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | 1.6 | 2.0 | 11.2 |
| Total Revenues | 1.6 | 2.0 | 11.2 |
| Operating Expenses & Income | |||
| R&D Expenses | 10.2 | 8.6 | 7.4 |
| Operating Income | (12.6) | (10.4) | (1.2) |
| Earnings from Continuing Operations | |||
| Interest & Investment Income | 0.7 | 0.7 | 1.1 |
| Other Non-Operating Income / Expenses | 0.7 | 0.7 | 1.2 |
| EBT, Incl. Unusual Items | (11.9) | (9.6) | 0.0 |
| Income Tax Expense | — | 0.0 | 0.0 |
| Net Income | |||
| Net Income | (11.9) | (9.6) | 0.0 |
| Per Share | |||
| Basic EPS | (1.44) | (1.77) | — |
| Diluted EPS | (1.44) | (1.69) | — |
| Revenue per Share | 0.19 | — | — |
| Basic Weighted Avg Shares | 8.2 | 5.4 | 5.3 |
| Diluted Weighted Avg Shares | 8.2 | 5.7 | 5.4 |
| Supplemental | |||
| EBITDA | — | (10.3) | (1.1) |
| EBIT | (12.6) | (10.4) | (1.2) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.